<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945005</url>
  </required_header>
  <id_info>
    <org_study_id>101214</org_study_id>
    <nct_id>NCT04945005</nct_id>
  </id_info>
  <brief_title>Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation Registry</brief_title>
  <acronym>PLACE</acronym>
  <official_title>Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry for patients undergoing pacemaker/ICD implantation including a transtricuspid lead&#xD;
      with and without intraprocedural transesophageal echocardiography to evaluate risk factors&#xD;
      for lead induced tricuspid regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lead induced tricuspid regurgitation is a common finding after pacemaker/ICD Implantation.&#xD;
      Transesophageal echocardiography (TEE) might be used to guide lead implantations in order to&#xD;
      prevent tricuspid regurgitation.&#xD;
&#xD;
      In this registry, patients undergoing pacemaker/ICD implantation including a transtricuspid&#xD;
      lead are enrolled. While in most patients lead implantation is guided by fluroscopy, in some&#xD;
      patients lead implantation is guided by TEE in addition to fluroscopy.&#xD;
&#xD;
      Aims of this registry: Evaluation of&#xD;
&#xD;
        -  Incidence of lead induced tricuspid regurgitation&#xD;
&#xD;
        -  Mortality and morbidity of lead induced tricuspid regurgitation&#xD;
&#xD;
        -  Identification of risk factors for lead induced tricuspid regurgitation&#xD;
&#xD;
        -  Influence of the lead position within the tricuspid valve on the incidence of lead&#xD;
           induced tricuspid regurgitation&#xD;
&#xD;
        -  Prevention of lead induced tricuspid regurgitation by TEE-guided lead implantation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Increase of tricuspid regurgitation by at least one grade (on a scale from 0-4)</measure>
    <time_frame>2 - 7 days post-implant (at hospital discharge)</time_frame>
    <description>Lead induced tricuspid regurgitation measured by transthoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-are product</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Dose-are product applied during lead implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead revisions</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of acute lead revisions within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of tricuspid regurgitation by at least one grade (on a scale from 0-4)</measure>
    <time_frame>3 months</time_frame>
    <description>Lead induced tricuspid regurgitation measured by transthoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of tricuspid regurgitation by at least one grade (on a scale from 0-4)</measure>
    <time_frame>12 months</time_frame>
    <description>Lead induced tricuspid regurgitation measured by transthoracic echocardiography</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Pacemaker Complication</condition>
  <condition>Echocardiography, Transesophageal</condition>
  <arm_group>
    <arm_group_label>Lead implantation with transesophageal echocardiography</arm_group_label>
    <description>All patients undergoing pacemaker/CRT implantation with concomitant transesophageal echocardiography in addition to fluoroscopic guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead implantation without transesophageal echocardiography (retrospective)</arm_group_label>
    <description>All patients undergoing standard pacemaker/CRT implantation guided by fluoroscopy only (retrospective historical control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transesophageal guidance of lead implantation</intervention_name>
    <description>In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions</description>
    <arm_group_label>Lead implantation with transesophageal echocardiography</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients undergoing pacemaker/ICD implantation including a transtricuspid lead&#xD;
        were included in this registry.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  indication for pacemaker/ICD implantation including a transtricuspid lead according to&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pre-existing RV lead&#xD;
&#xD;
          -  pre-existing TR &gt;2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Braun, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Klinikum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LMU Klinikum</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Daniel Braun, MD</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

